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A heparin-bonded vascular graft generates no
systemic effect on markers of hemostasis activation
or detectable heparin-induced thrombocytopenia–
associated antibodies in humans
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Objectives: Almost a third of patients who undergo peripheral bypass procedures do not have suitable veins, making the
use of prosthetic materials necessary. Prosthetic materials can cause platelet adhesion and activation of the coagulation
cascade on the graft. One potential strategy to reduce this thrombogenicity is to covalently bind heparin to the
endoluminal surface of grafts. This human in vivo study examined systemic effects of the endoluminal heparin and
addressed whether graft implantation results in (1) a measurable reduction of systemic markers of hemostasis activation
compared with control grafts and (2) antibody formation against heparin, potentially responsible for heparin-induced
thrombocytopenia (HIT).
Methods: The study included 20 patients undergoing femoropopliteal bypass grafting, of whom 10 received a standard
Gore-Tex Thin Walled Stretch Vascular Graft (W. L. Gore & Associates, Flagstaff, Ariz) and 10 received a heparin-
bonded expanded polytetrafluoroethylene (ePTFE) graft (Gore-Tex Propaten Vascular Graft). Blood samples were
drawn before and directly after the operation and at days 1, 3, 5, and week 6 after surgery. Established markers of in vivo
activation of platelets and blood coagulation (prothrombin fragment 12, fibrinopeptide A, soluble glycoprotein V,
thrombin-antithrombin complexes, and D-dimers) were measured using standard commercially available techniques.
Antiplatelet factor 4/heparin antibody titers were measured using a commercially available enzyme-linked immunosor-
bent assay, and platelet counts were determined.
Results: No statistical differences were observed in any of the markers of in vivo activation of platelets and blood
coagulation between patients receiving Propaten or control ePTFE. Moreover, no antibodies against heparin could be
demonstrated up to 6 weeks after implantation.
Conclusions: No measurable effect of heparin immobilization on systemic markers of hemostasis was found using a
heparin-bonded ePTFE graft in vivo. Also, no antibodies against heparin could be detected up to 6 weeks after
implantation. (J Vasc Surg 2008;47:324-9.)Almost a third of patients who need peripheral arterial
reconstructive operations do not have suitable autologous
veins available for grafting.1 For that reason, prosthetic
grafts, such as those made from polytetrafluoroethylene
(PTFE), are frequently used in arterial bypass procedures.
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324Autologous veins, however, have better patency than pros-
thetic grafts. A recent review comparing venous and PTFE
above knee femoropopliteal bypasses reported 5-year pri-
mary patency rates of 74% and 39%, respectively.2
Apart from this clinical evidence, laboratory models
also have shown that PTFE grafts are substantially more
thrombogenic compared with autologous veins. Prosthetic
materials can cause platelet adhesion and activation of the
coagulation cascade on the graft.3 One potential strategy to
reduce this thrombogenicity is to covalently bind heparin
to the endoluminal surface of grafts.
Heparin is a polysaccharide anticoagulant with potent
inhibitory effects on coagulation and a long history of
clinical use in the prevention and treatment of thrombosis.4
Long-term systemic use of heparin is hampered by the
immunogenicity of the heparin/platelet factor 4 (PF4)
complex. Heparin-induced thrombocytopenia without
(HIT) or with thrombosis (HITT) is a serious complication
of heparin administration, with an estimated incidence of
approximately 3%, although the percentage of patients
experiencing serious symptoms is much lower. Even short-
term administration of heparin may be associated with HIT
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out clinically overt symptoms. These antibodies lead to
platelet activation resulting in thrombocytopenia as a con-
sequence of immune-mediated clearance and consump-
tion. Furthermore, the coagulation cascade may also be
activated, resulting in thrombosis, which occurs in approx-
imately one-third of patients with HIT.5 These thromboses
are clinically relevant in about 50% of the patients, and these
patients have a poor prognosis: 20% will lose a limb, and
30% eventually die.6
Heparin-bonded (or heparinized) grafts have shown
favorable results with respect to graft patency in animal
models and humans compared with untreated vascular
grafts.7-9 In fact, a recent analysis showed that the heparin-
ized graft used in this study gives patency rates comparable
with rates for autologous veins.10 The beneficial effects of
heparinized grafts appear particularly caused by a substan-
tial reduction in acute graft thrombosis within weeks after
implantation. Clinical evidence thus suggests that heparin-
bonded grafts are superior to untreated grafts. Studies on
the mechanism by which heparin immobilized on the grafts
prevents graft thrombosis are scarce.
A new expanded PTFE (ePTFE) graft with long-term
bonding of heparin accomplished by covalent linkage of the
anticoagulant is commercially available in several European
countries and has been approved by the United States Food
and Drug Administration for use in the United States since
2006. We recently developed a human ex vivo model
comparing this heparin-bonded graft with untreated
ePTFE and concluded that heparin bonding substantially
reduces the thrombogenicity of ePTFE grafts.11 Whether
this translates in a systemic anticoagulant effect is unknown
and was the focus of our study.
The fact that the heparin is covalently bonded to these
grafts raises an important question with respect to antige-
nicity. It is unknown whether surface-bonded heparin is
able to elicit an immunogenic response similar to that of
heparin in solution. Thus, this study examined systemic
effects of the local presence of heparin and specifically
addressed whether graft implantation results in (1) a mea-
surable reduction of systemic markers of hemostasis activa-
tion compared with control grafts and (2) antibody forma-
tion against heparin, potentially responsible for HIT. The
thrombotic markers used in the proposed study are gener-
ally accepted as predictors of thrombotic complications in
vivo.12
MATERIAL AND METHODS
Study population. The study population included 20
patients, all of whom signed a patient informed consent
form to participate in the study. Each study subject received
an infrainguinal bypass with a Gore-Tex e-PTFE Vascular
Graft (W. L. Gore & Associates, Flagstaff, Ariz). Ten
subjects received a Gore-Tex Propaten Vascular Graft, and
10 subjects received a Gore-Tex Thin Walled Stretch Vas-
cular Graft. Patients were assigned to two groups in alter-
nating order, and the first treatment was selected by com-
puter-assisted randomization. They were sequentiallyincluded. Patients were excluded if aged 18 years old, if
no informed consent could be given, or if they had a known
history of heparin allergy. All patients were included in the
University Medical Center Utrecht. Three vascular sur-
geons performed the operations.
All patients were on standard intraoperative and postop-
erative regimens as applied in our institution: 5000 IU of
unfractionated heparin was administered just before clamp-
ing, and afterwards, low-molecular-weight heparin (LMWH)
was given once daily at a fixed time during the day (17:00
hours) during the entire hospital stay. The two study groups
were therefore comparable in terms of postoperative medica-
tion.
Vascular grafts. All vascular grafts used in the study
were 6-mm Gore-Tex e-PTFE Vascular Grafts from the
standard hospital inventory. Patient assignment to a specific
graft-type treatment group, Gore-Tex Propaten Vascular
Graft or Gore-Tex Thin Walled Stretch Vascular Graft,
followed a systematic, alternating-type methodology initi-
ated at the beginning of the study to establish the starting
treatment group assignment and the order of subsequent
treatment group assignments. Surgeons were aware of the
material used; however, because outcome was determined
only by laboratory assays on blood samples, which were
blinded to the laboratory team, a lack of bias was assured.
Blood sampling. Peripheral blood samples were col-
lected preoperatively, directly postoperatively, before ad-
ministration of 2500 or 5000 IU once daily postoperative
LMWH (Fragmin, Pfizer Health AB/Eisai, Woodcliff
Lake, NJ) for thromboprophylaxis, and at subsequent post-
operative intervals of 1, 3, and 5 days, and at 6 weeks.
Patients who weighed 75 kg received 5000 IU of
LMWH, those 75 kg received 2500 IU. Because both
groups were treated according to this standard regimen,
the influence of the LMWH on outcome was, theoretically,
neutralized.
All postoperative blood samples were collected imme-
diately before administration of daily LMWH during the
hospital stay. Blood was obtained from the antecubital vein
according to standardized venipuncture procedures and
collected in tubes containing sodium citrate. Although this
study was not performed blinded for the surgical team, the
samples were blinded before the laboratory analyses were
done.
Systemic marker assays. Prothrombin fragment 12
(F12), which is removed from prothrombin when this
proenzyme is activated to the enzyme thrombin, was mea-
sured with an F12-specific enzyme-linked immunosorbent
assay (ELISA; Enzygnost F12 Micro, Dade Behring,
Marburg, Germany). Fibrinopeptide A (FPA), which is
removed from fibrinogen upon conversion to fibrin, was
measured with an FPA ELISA assay (Zymutest FPA, Hy-
phen Biomed, Andresy, France). Thrombin-antithrombin
(TAT) complexes, which reflect the amount of thrombin
generated, were measured with a TAT-specific ELISA (Di-
agnostica Stago, Asnieres-Sur-Seine, France). Soluble gly-
coprotein V (sGPV), which is removed from the platelet
surface following platelet activation, was measured with an
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were measured with an Asserachrom D-DI ELISA kit (Di-
agnostica Stago). Antibodies against the PF4 complex were
measured by a sensitive ELISA assay (GTI Diagnostics,
Waukesha, Wisc), which is able to detect low-titer antibod-
ies, and is nearly as sensitive as the serotonin-release assay,
which is considered the golden standard of HIT diagnos-
tics. Platelet counts were determined according to standard
hospital methods.
Follow-up. Patients underwent physical examination
by a medical doctor directly after operation, before dis-
charge, and at the outpatient clinic after 6 weeks to check
the status of the graft implanted.
Statistical analyses. Data for systemic markers in the
peripheral blood samples from patients with Gore-Tex
Propaten and Gore-Tex Thin Walled Stretch Vascular
Grafts were compared at each time point with a standard t
test. Progression of platelet counts in time was assessed by
repeated one-way analysis of variance (ANOVA) with the
Tukey post-test. P .05 was considered statistically signif-
icant.
RESULTS
The study initially included 21 patients (8 women), and
their average age was 72 years (range, 62-78 years), Pa-
tients receiving ePTFE or Propaten grafts were comparable
in terms of age and sex distribution. All patients had un-
complicated procedures, and all bypasses were implanted
infrainguinally. All patients were discharged 1 week after
operation.
One patient was excluded and analyzed separately, and
20 patients were analyzed as a group. A regular ePTFE graft
was implanted in the excluded patient, but a systemic
heparin infusion was needed during 4 days postoperatively
owing to the anticipated risk of progressive leg ischemia
after the procedure. All markers were measured in this
patient because a decline in platelet count or an antibody
against heparin might be detected. This patient also had an
uneventful recovery.
At the long-term follow-up (6 weeks), all grafts were
patent, as was concluded from the physical exam at the
outpatient clinic. If patency of the graft was in doubt,
duplex ultrasound scanning was to be performed, but this
was not necessary in any of the patients.
No substantial or statistically significant differences
were observed in any of the markers of in vivo activation of
platelets and blood coagulation between patients receiving
Propaten or control ePTFE grafts (Fig 1). Platelet counts
stayed relatively constant after surgery. In the Propaten
group, a 20% decrease in platelet count was observed at day
1 after surgery compared with baseline values, but this
difference was not statistically significant, and platelet
counts were already normalized again at day 3. At day 5,
platelet counts were 23% higher compared with baseline
values in the Propaten group (P  .05, Fig 2).
In contrast, the patient who was not included in the
study population because of the administration of intrave-
nous heparin, yet analyzed, showed a progressive decreasein platelet count after surgery, with a percentage nadir value
of 55% compared with the platelet count before surgery
(Fig 3). Moreover, antibodies against heparin were de-
tected at day 3 and 5, without clinically overt manifesta-
tions of HIT. At week 6, the amount of platelets almost
returned to the preoperative count and antibodies against
heparin could still be detected. On the other hand, no
antibodies against heparin could be demonstrated up to 6
weeks after implantation in the primary study population.
DISCUSSION
This study evaluated in a human in vivo setup whether
implantation of an infrainguinal heparinized graft results in
(1) a measurable reduction of systemic markers of hemo-
stasis activation compared with control grafts and (2) anti-
body formation against heparin, potentially responsible for
HIT.
Recent data show that the short-term 1-year primary
patency of below knee Propaten bypass grafts is about 80%,
which is comparable with vein grafting.10 The reason for
this improved patency compared with standard ePTFE
grafts (66% primary patency) is unknown. From a prospec-
tive multicenter trial describing a 5-year follow-up study
comparing heparinized Dacron (DuPont, Wilmington,
Del) grafts with PTFE grafts, we know that the beneficial
effects of the heparin graft were particularly evident in the
early weeks after implantation and sustained thereafter.9
This suggests that the thrombogenicity reduction due to
the heparinization resulting in a decreased occurrence of
acute graft thrombosis is at least partly responsible for the
improved patency in favor of the heparin-bonded Dacron
graft. Another explanation for the improved patency might
be the reduction of the development of intimal hyperplasia,
because heparin is known to reduce the migration of
smooth muscle cells that are responsible for the formation
of intimal hyperplasia.13-17
Our research group, however, recently concluded from
a human ex vivo model comparing heparinized with un-
treated ePTFE that heparin bonding substantially reduces
the thrombogenicity of ePTFE grafts,11 but it was still
unknown whether this translates into a systemic anticoag-
ulant effect. It is also unknown whether antibodies can be
formed against the locally bonded heparin. This might be
of great clinical importance, not only because of the possi-
ble development of HIT(T) but also because of antibody
formation against heparin that is clinically nonrelevant but
which might imply a life-time prohibition of heparin use.
We could not demonstrate an effect of heparin immo-
bilization on systemic activation of hemostasis using mark-
ers of platelet activation (sGPV), thrombin generation
(F12), thrombin inactivation (TAT), and fibrin generation
(FPA). In contrast, our recent ex vivo study did show
profound inhibitory effects of heparin immobilization on
platelet deposition and fibrin formation.9 The reason that
the local antithrombotic effects of the immobilized heparin
does not translate to a detectable reduction of markers of
platelet activation or fibrin generation measured in the
systemic circulation may be explained by a dilutional effect.
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fraction of the entire vasculature, and this may explain why
the local inhibition of platelet activation and fibrin genera-
tion by the heparin on the graft does not result in a
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Fig 1. Mean levels of markers of coagulation or platelet activation
in patients receiving plain expanded polytetrafluoroethylene
(ePTFE) or Propaten grafts (W. L. Gore & Associates, Flagstaff,
Ariz) at various times after surgery compared with preoperative
levels. Error bars indicate standard error of mean. sGPV, soluble
glycoprotein V; F12, prothrombin fragment 12; FPA, fibrino-
Fig 2. Mean platelet count of patients receiving either a Propaten
(W.L. Gore & Associates, Flagstaff, Ariz) or expanded polytetra-
fluoroethylene (ePTFE) graft at various times before and after
surgery. Error bars indicate standard error of mean.
Fig 3. Absolute platelet count of a patient who received an ex-
panded polytetrafluoroethylene (ePTFE) graft but was excluded from
the analysis because systemic heparin was needed for 4 days postop-
eratively. A 45% decline in platelet count was observed at day 5, which
recovered up to normal levels at week 6; moreover, no heparin/
platelet factor 4 complex antibodies developed in this patient.peptide A; TAT, thrombin-antithrombin complexes.
JOURNAL OF VASCULAR SURGERY
February 2008328 Heyligers et aldetectable systemic antithrombotic effect. A theoretic ap-
proach to investigate an in vivo antithrombotic effect of
heparinized grafts would involve sampling of blood right
after the prosthesis, which is in practice not feasible.
Alternatively, the present study may be underpowered
to detect differences. The study was designed as an obser-
vational study, and in the relatively small number of sub-
jects studied, no differences or trends towards differences in
the measured markers were observed. If a much larger
study were to show differences, they would likely be small
and not have substantial clinical relevance.
A potential confounder in our study is the administra-
tion of LMWH heparin as thromboprophylaxis. Adminis-
tration of LMWH could potentially affect the hemostasis
markers as measured in our study. The goal of our study,
however, was to investigate a potential effect of heparin-
bonded grafts in patients undergoing standard medical
care, because it is with this regimen that substantial differ-
ences in patency between heparin-bonded and bare grafts
have been observed. Thus, although postoperative LMWH
is a potential confounder, it is part of standard medical care
in patients who receive ePTFE or Propaten grafts. We
attempted to minimize LMWH interference with the mea-
surement of hemostasis markers by sampling just before the
daily LMWH injection, when circulating LMWH would be
at the lowest possible level. We believe this approach results
in a fair comparison. In addition, it would be ethically
unacceptable to withhold LMWH in these patients because
of the risk of graft-related and deep vein thrombosis.
We did not detect any antibodies against heparin/PF4
in the patients who received a Propaten graft, even after 6
weeks of implantation. We did observe a 20% decrease in
platelet count in the Propaten group 1 day after surgery,
but this decrease was not statistically significant and re-
solved again at day 3; thus, we do not believe that this
temporal drop in platelet count reflects the activity of very
low titer (undetectable by our assay) heparin/PF4 antibod-
ies. That we did not detect antibodies against heparin/PF4
even at 6 weeks after surgery might imply that the immo-
bilized heparin does not elicit an immune response such as
frequently observed with systemic (intravenous) heparin.
The apparent nonimmunogenic nature of the Propaten
grafts contrasts with grafts to which heparin is coated
noncovalently. With these grafts, the heparin was observed
to be immunogenic as a result of leakage of heparin from
the graft.18,19 This leakage does not occur with Propaten
grafts to which heparin is bonded covalently.7,8
Although systemic heparin infusion is only possible for
a few days because of the high risk of antibody development
against heparin/PF4 potentially leading to HIT(T), im-
plantation of Propaten grafts does not result in formation of
these antibodies even after 6 weeks. The immobilized hep-
arin is still active after 6 weeks as shown by animal experi-
ments.7 To our knowledge, this is the first report of surveil-
lance of antibody development after prolonged (6 weeks)
in vivo exposure to immobilized heparin.
A single patient did receive intravenous heparin after
implantation of an ePTFE graft and had a substantial drop(45%) in platelet count associated with the development of
low-titer antiheparin/PF4 antibodies in the absence of
overt HIT, indicating that clinically silent HIT(T) can be
detected with our assay methods.
CONCLUSION
The results of this study indicate that heparin-coated
vascular grafts do not result in a measurable systemic
thromboresistant effect and also do not result in develop-
ment of HIT-inducing antibodies even after 6 weeks of
implantation. The reason for the lack of immunogenicity of
immobilized heparin is unclear, but is beneficial because
this does not prohibit future use of intravenous heparin.
AUTHOR CONTRIBUTIONS
Conception and design: JH, TL, HV, PG, FM
Analysis and interpretation: JH, TL, CW
Data collection: JH, TL, CW
Writing the article: JH, TL
Critical revision of the article: JH, TL, HV, CW, PG, FM
Final approval of the article: JH, TL, HV, PG, CW, FM
Statistical analysis: JH, TL, CW
Obtained funding: PG, FM
Overall responsibility: JH, FM
REFERENCES
1. Sayers RD, Raptis S, Berce M, Miller JH. Long-term results of femo-
rotibial bypass with vein or polytetrafluoroethylene. Br J Surg 1998;85:
934-8.
2. Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus
PTFE for above-knee femoropopliteal bypass. A review of the literature.
Eur J Vasc Endovasc Surg 2004;27:357-62.
3. Heyligers JM, Arts CH, Verhagen HJ, de Groot PG, Moll FL. Improv-
ing small-diameter vascular grafts: from the application of an endothelial
cell lining to the construction of a tissue-engineered blood vessel. Ann
Vasc Surg 2005;19:448-56.
4. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and
pharmacology of unfractionated heparin. Arterioscler Thromb Vasc
Biol 2001;21:1094-6.
5. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb
J 2005;3:14.
6. Ananthasubramaniam K, Shurafa M, Prasad A. Heparin-induced
thrombocytopenia and thrombosis. Prog Cardiovasc Dis 2000;42:247-
60.
7. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gallhagen A.
Improvements in GORE-TEX vascular graft performance by Carmeda
BioActive surface heparin immobilization. Eur J Vasc Endovasc Surg
2003;25:432-7.
8. Lin PH, Chen C, Bush RL, Yao Q, Lumsden AB, Hanson SR. Small-
caliber heparin-coated ePTFE grafts reduce platelet deposition and
neointimal hyperplasia in a baboon model. J Vasc Surg 2004;39:
1322-8.
9. Devine C, McCollum C. Heparin-bonded Dacron or polytetrafluoreth-
ylene for femoropopliteal bypass: five-year results of a prospective
randomized multicenter clinical trial. J Vasc Surg 2004;40:924-31.
10. Bosiers M, Deloose K, Verbist J, Schroe H, Lauwers G, Lansink W, et al.
Heparin-bonded expanded polytetrafluoroethylene vascular graft for
femoropopliteal and femorocrural bypass grafting: 1-year results. J Vasc
Surg 2006;43:313-8.
11. Heyligers JM, Verhagen HJ, Rotmans JI, Weeterings C, de Groot PG,
Moll FL, et al. Heparin immobilization reduces thrombogenicity of
small-caliber expanded polytetrafluoroethylene grafts. J Vasc Surg
2006;43:587-91.
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 2 Heyligers et al 32912. van der Putten RF, Glatz JF, Hermens WT. Plasma markers of activated
hemostasis in the early diagnosis of acute coronary syndromes. Clin
Chim Acta 2006 Sep;371:37-54.
13. Caplice NM, West MJ, Campbell GR, Campbell J. Inhibition of human
vascular smooth muscle cell growth by heparin. Lancet 1994;344:97-8.
14. Herbert JM, Bono F, Lamarche I, Carmeliet P. The inhibitory effect of
heparin for vascular smooth muscle cell proliferation or migration is not
mediated by u-PA and t-PA. Thromb Res 1997;86:317-24.
15. Koyama N, Kinsella MG, Wight TN, Hedin U, Clowes AW. Heparan
sulfate proteoglycans mediate a potent inhibitory signal for migration of
vascular smooth muscle cells. Circ Res 1998;83:305-13.
16. Kanamasa K, Otani N, Ishida N, Inoue Y, Morii H, Ishikawa K. A 7-day
administration of tPA or heparin in the prevention of intimal hyperplasia
of these patients develop heparin-induced thrombocytopenia, butfollowing vascular injury in atherosclerotic rabbits. J Interv Cardiol
2002;15:191-5.
17. Ao PY, Hawthorne WJ, Coombs R, Fletcher JP. Suppression of intimal
hyperplasia with low molecular weight heparin in a sheep model. Int
Angiol 1999;18:131-9.
18. Almeida JI, Liem TK, Silver D. Heparin-bonded grafts induce platelet
aggregation in the presence of heparin-associated antiplatelet antibod-
ies. J Vasc Surg 1998;27:896-900.
19. Laster J, Silver D. Heparin-coated catheters and heparin-induced
thrombocytopenia. J Vasc Surg 1988;7:667-72.Submitted Jun 21, 2007; accepted Oct 8, 2007.DISCUSSION
Dr Karthik Kasirajan (Atlanta, Ga): I thank the authors for
getting me the manuscript in a timely fashion. And I certainly think
that this is a very timely paper given recent FDA approval for the
Propaten graft. In their paper, the authors attempt to study if the
surface heparin would elicit the same immunogenic response as
systemic administration of heparin. Heparin-bonded ePTFE grafts
are compared in humans to standard thin wall stretch ePTFE grafts
implanted in a similar location. The authors have evaluated the
systemic markers of hemostasis and antibody formation against
heparin in 20 patients, which is about 10 patients in each arm.
A 20% drop in platelet counts seen in the Propaten group did
not achieve statistical significance This drop was noted in the early
postoperative repair. The authors in conclusion attempt to explain
the lack of systemic effects of heparin as possibly secondary to
dilution or secondary to the covalent bonding of heparin to the
Propaten grafts. That brings me to a few questions.
What is the overall incidence of HIT I and HIT II seen on a
general population of patients receiving heparin? I assumed this is
quite low. We use heparin almost on a daily basis and rarely see a
patient with overt manifestations of HIT. The reason I asked this
question is, given the low incidence of HIT and the fact that you
have only 10 patients in each arm, is it possible that you have a type
2 error or a false-negative result given the small sample size? That’s
my first question.
It is also my understanding that the HIT syndrome is an
immune-mediated response and not a dose-dependent phenome-
non. Patients with a prior HIT syndrome cannot receive even small
dose of heparin after the initial diagnosis has been established.
Hence, I’m not sure I agree with the argument that covalent
bonding or dilution prevents the manifestation of HIT in patients
receiving the Propaten graft. Hence, I feel that this study has not
sufficiently powered to demonstrate a HIT response. Given the
authors’ conclusion, and the title of their paper, do the authors feel
confident, based on the study, to implant a Propaten graft in the
patient with a known HIT syndrome? Thank you very much.
Dr Felix Schlosser: You asked what the incidences of HIT I
and HIT II were after intravenous heparin and if there could be
possibly a type 2 error in our study. Well, I have to agree that the
number of patients in our study is low and therefore there could be
a type 2 error. However, to our knowledge, this is the first study
that has surveillance of such a long time in these patients for
antibody formation. There is no better evidence available at this
moment. The number of patients is low; however, our evidence is
the first evidence that has followed these patients and these growth
markers for quite a long time, and we are at this moment collecting
more data. We are collecting the 1-year data of those patients, and
we hope to show more improved evidence when we have collected
all these data.
The other part of your question, the patients that received
intravenous heparin: I don’t know the exact number of how manya large proportion of these patients, around 20% to 30%, will
develop it after a prolonged time of heparin dosages. They will
develop antibodies against the heparin/platelet factor 4 complex;
however, not all of these patients develop heparin-induced throm-
bocytopenia. About 1% to 2% of patients that received heparin
during a prolonged time developed a heparin-induced thrombo-
cytopenia, and 50% of those patients suffered from clinically rele-
vant thrombosis. If the number of patients that develop antibodies
against the heparin is about 20% and the number of patients that
really suffer from heparin-induced thrombocytopenia is 1% to 2%,
it’s only a small percentage of the total amount of patients that
develop antibodies against the heparin/platelet factor 4 complex.
We have in our study 10 patients who did not develop those
antibodies or other blood products that were side effects of the
heparin that was covalently bonded to the prosthesis. There are few
patients that develop those antibodies, and if there was a patient
that developed antibodies, there is also a small chance that these
antibodies will lead to heparin-induced thrombocytopenia.
It is also important to realize that we do not state or conclude
that covalent bonding or dilution of heparin prevents the develop-
ment of HIT. What we conclude from our study is that in these
patients no antibodies against heparin could be detected, even after
exposure of 6 weeks. This is the first human study, as far as we
know, that looked for detection of antibodies against heparin in
this timeframe.
We do not feel confident to implant a heparin-bonded graft in
patients with known HIT on the basis of these data, simply because
this study does not address this question and therefore can not be
recommended.
Dr Allen Hamdan (Boston, Mass): I have just a couple of
questions. I assume you used ELISA test, and why not the seroto-
nin release assay as part of it? And can you give a little bit more
information on the patient that was excluded? I didn’t quite
understand what happened.
Dr Schlosser: Thank you for the question. You asked why
we’re using ELISA. The sensitivity and the specificity ELISA is
quite good. Sensitivity is 99% to detect antibodies against the
heparin/platelet factor 4 complex, and specificity is 100%. The
excluded patient had a risk to develop progressive leg ischemia, and
therefore the surgeon started heparin infusion during day 1 until
day 4. Because she got heparin intravenously, she was excluded
from the analysis, because otherwise, the results would change our
outcome drastically.
Dr. Hamdan: But that patient did develop HIT? One of the
conclusions would be maybe systemic heparinization with a hepa-
rin-bonded graft increases risk.
Dr. Schlosser: That patient did not develop HIT, but devel-
oped antibodies against heparin/platelet factor 4 complex. I can
add that this patient did not have a Propaten graft but a thin
stretchable graft. It is clear that the cause of the antibodies in these
patients were from the intravenous heparin.
